Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04508907 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
A Phase 4 study of Hepatitis C and Kidney Transplant; Complications, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT04508907 is a Phase 4 study of Hepatitis C and Kidney Transplant; Complications that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 200 participants, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04508907, a Phase 4 study of Hepatitis C and Kidney Transplant; Complications, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
Conditions Studied
Interventions
- DRUG Mavyret
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04508907
The ClinicalTrials.gov registry entry for NCT04508907 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (89% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Mavyret is the first listed.
NCT04508907 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT04508907 about?
NCT04508907 is a clinical study titled "A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients". This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
What is the current status of trial NCT04508907?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2020-09-10. Estimated completion is 2026-11-01.
What conditions does trial NCT04508907 study?
This clinical trial studies the following conditions: Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection.
What interventions are being tested in trial NCT04508907?
The interventions under investigation include: Mavyret (DRUG).
Who is sponsoring clinical trial NCT04508907?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04508907 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
-
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.